title: Childhood psoriasis: often favorable outcome.
abstract: (1) Plaque psoriasis is the most common form of psoriasis in children. Topical agents should be tried first, especially well-tolerated products such as emollients. Topical corticosteroids are sometimes useful during exacerbations but, given adverse effects, they should only be used for short periods; (2) UVB phototherapy is an option for extensive psoriasis refractory to local treatments, but it carries a long-term risk of skin cancer. Immunosuppressants have not been well assessed in this setting, but methotrexate has been better evaluated than the others.
mesh_terms: D017255:Acitretin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D000287:Administration, Topical; D000875:Anthralin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D002117:Calcitriol / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives / Q000627:therapeutic use; D002648:Child; D016572:Cyclosporine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D003879:Dermatologic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D004643:Emollients / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D000068800:Etanercept; D006801:Humans; D007074:Immunoglobulin G / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D008727:Methotrexate / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D009539:Nicotinic Acids / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D010936:Plant Extracts / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D011565:Psoriasis / Q000188:drug therapy* / Q000628:therapy; D018124:Receptors, Tumor Necrosis Factor / Q000008:administration & dosage / Q000627:therapeutic use; D012459:Salicylates / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D013256:Steroids / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D013638:Tars / Q000009:adverse effects / Q000627:therapeutic use; D016896:Treatment Outcome; D014467:Ultraviolet Therapy; D012176:Retinoids
chemical_list: D017255:Acitretin; D000875:Anthralin; D002117:Calcitriol; D016572:Cyclosporine; D003879:Dermatologic Agents; D004643:Emollients; D000068800:Etanercept; D007074:Immunoglobulin G; D007166:Immunosuppressive Agents; D008727:Methotrexate; D009539:Nicotinic Acids; D010936:Plant Extracts; D018124:Receptors, Tumor Necrosis Factor; D012459:Salicylates; D013256:Steroids; D013638:Tars; C055085:calcipotriene; C062613:juniper tar; C086827:tazarotene; D012176:Retinoids